IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden spoke with Proactive about the company’s innovation-led growth strategy, highlighting advances in its AI-powered neuroimaging platform.
He said new vascular biomarkers for Alzheimer’s are due in Q3, followed by a neuromelanin biomarker for Parkinson’s in Q4, strengthening IXICO’s differentiation in CNS-focused clinical research. “We’re the only imaging analytics company fully focused on the brain,” Goorden said.
IXICO is expanding its footprint in the US, deepening partnerships with pharma and biotech, and broadening its addressable market beyond Huntington’s into Alzheimer’s and Parkinson’s. The company is also targeting new revenue streams in post-marketing surveillance and clinical decision support.
A £13m-plus order book provides full revenue visibility for 2025 and around 75% visibility for 2026, with further upside expected as more Alzheimer’s therapies progress.
